Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients’ experiences in Australia
Anthony Barnett, Michael Savic, Nicholas Lintzeris, et al.
Drug and Alcohol Dependence (2021) Vol. 227, pp. 108959-108959
Open Access | Times Cited: 49

Showing 1-25 of 49 citing articles:

The Impact of Stigma on People with Opioid Use Disorder, Opioid Treatment, and Policy
Ali Cheetham, Louisa Picco, Anthony Barnett, et al.
Substance Abuse and Rehabilitation (2022) Vol. Volume 13, pp. 1-12
Open Access | Times Cited: 117
Can a new formulation of opiate agonist treatment alter stigma?: Place, time and things in the experience of extended-release buprenorphine depot
Carla Treloar, Kari Lancaster, Sandra Gendera, et al.
International Journal of Drug Policy (2022) Vol. 107, pp. 103788-103788
Open Access | Times Cited: 35
Patient perspectives on depot buprenorphine treatment for opioid addiction – a qualitative interview study
Björn Johnson, Olivia Liahaugen Flensburg, Andrea Johansson Capusan
Substance Abuse Treatment Prevention and Policy (2022) Vol. 17, Iss. 1
Open Access | Times Cited: 28
Tinkering with care: Implementing extended-release buprenorphine depot treatment for opioid dependence
Kari Lancaster, Sandra Gendera, Carla Treloar, et al.
International Journal of Drug Policy (2024) Vol. 126, pp. 104359-104359
Open Access | Times Cited: 6
The uptake of long‐acting depot buprenorphine for treating opioid dependence in Australia, 2019–2022: longitudinal sales data analysis
Nicholas Lintzeris, Victoria Hayes, Adrian Dunlop
The Medical Journal of Australia (2024) Vol. 220, Iss. 6, pp. 339-340
Open Access | Times Cited: 4
The dynamics of more-than-human care in depot buprenorphine treatment: A new materialist analysis of Australian patients’ experiences
Anthony Barnett, Kiran Pienaar, Dan I. Lubman, et al.
International Journal of Drug Policy (2024) Vol. 127, pp. 104399-104399
Open Access | Times Cited: 4
Treatment satisfaction and patient reported outcomes among people with opioid use disorder participating in an open‐label, non‐randomised trial of long‐acting injectable buprenorphine treatment in Australian custodial settings
Bethany White, Sophia C. Little, Paul Haber, et al.
Drug and Alcohol Review (2025)
Open Access
Making long‐acting treatment work: Tracing connections with extended‐release buprenorphine depot through time
Sandra Gendera, Kari Lancaster, Tim Rhodes, et al.
Drug and Alcohol Review (2025)
Open Access
Changing patterns of opioid agonist therapy prescribing in a network of specialised clinics providing care to people with opioid use disorder in Victoria, Australia, 2015 to 2023
Joshua Dawe, Anna L. Wilkinson, M. David Curtis, et al.
Drug and Alcohol Review (2025)
Open Access
Long acting injectable buprenorphine: Perspectives from service-users, staff and stakeholders
Rebecca Fish, Céu Mateus, Hannah Maiden, et al.
Drug and Alcohol Dependence Reports (2025), pp. 100328-100328
Open Access
‘I just thought that was the best thing for me to do at this point’: Exploring patient experiences with depot buprenorphine and their motivations to discontinue
Simon Clay, Carla Treloar, Louisa Degenhardt, et al.
International Journal of Drug Policy (2023) Vol. 115, pp. 104002-104002
Open Access | Times Cited: 12
How do patients feel during the first 72 h after initiating long‐acting injectable buprenorphine? An embodied qualitative analysis
Joanne Neale, Stephen Parkin, John Strang
Addiction (2023) Vol. 118, Iss. 7, pp. 1329-1339
Open Access | Times Cited: 11
Qualitative study of patients’ decisions to initiate injectable depot buprenorphine for opioid use disorder: the role of information and other factors
Joanne Neale, Stephen Parkin, John Strang
Drugs Education Prevention and Policy (2023) Vol. 31, Iss. 2, pp. 189-199
Open Access | Times Cited: 9
Exploring patient experience and satisfaction with depot buprenorphine formulations: A mixed‐methods study
Eve Allen, Sona Samadian, Gary Altobelli, et al.
Drug and Alcohol Review (2023) Vol. 42, Iss. 4, pp. 791-802
Open Access | Times Cited: 9
Long-acting injectable depot buprenorphine from a harm reduction perspective in patients with ongoing substance use and multiple psychiatric comorbidities: a qualitative interview study
Björn Johnson, Bodil Monwell, Andrea Johansson Capusan
Harm Reduction Journal (2024) Vol. 21, Iss. 1
Open Access | Times Cited: 3
Long-acting injectable buprenorphine for opioid use disorder: A systematic review of impact of use on social determinants of health
Emily T. Martin, Hayley Maher, Gemma McKeon, et al.
Journal of Substance Abuse Treatment (2022) Vol. 139, pp. 108776-108776
Open Access | Times Cited: 14
The Social, Material, and Temporal Effects of Monthly Extended-Release Buprenorphine Depot Treatment for Opioid Dependence: An Australian Qualitative Study
Kari Lancaster, Sandra Gendera, Carla Treloar, et al.
Contemporary Drug Problems (2022) Vol. 50, Iss. 1, pp. 105-120
Closed Access | Times Cited: 14
Trends in use of medicines for opioid agonist treatment in Australia, 2013–2022
Chrianna Bharat, Kendal Chidwick, Natasa Gisev, et al.
International Journal of Drug Policy (2023) Vol. 123, pp. 104255-104255
Open Access | Times Cited: 8
96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial
Michael Farrell, Jeyran Shahbazi, Mark S. Chambers, et al.
International Journal of Drug Policy (2024) Vol. 127, pp. 104390-104390
Open Access | Times Cited: 2
Healthcare staff’s perspectives on long-acting injectable buprenorphine treatment: a qualitative interview study
Johan Nordgren, Bodil Monwell, Björn Johnson, et al.
Addiction Science & Clinical Practice (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 2
Compared implementation of the long-acting buprenorphine treatment buvidal in four European countries
Benjamin Rolland, Catriona Matheson, Ari Kaski, et al.
Expert Opinion on Drug Delivery (2024) Vol. 21, Iss. 5, pp. 809-815
Open Access | Times Cited: 2
Long-Acting Injectable Buprenorphine for Opioid Use Disorder: A Qualitative Analysis of Patients’ Interpersonal Relationships during the First Year of Treatment
Joanne Neale, John Strang
Substance Use & Misuse (2024) Vol. 59, Iss. 14, pp. 2064-2072
Open Access | Times Cited: 2
Barriers and facilitators to becoming an alcohol and other drug nurse practitioner in Australia: A mixed methods study
Adam Searby, Dianna Burr, Colleen Blums, et al.
International Journal of Mental Health Nursing (2023) Vol. 32, Iss. 3, pp. 839-853
Open Access | Times Cited: 6
Opioid‐related policy changes: Experiences and perspectives from people who use opioids to manage non‐cancer chronic pain
Sarah Haines, Michael Savic, Suzanne Nielsen, et al.
Drug and Alcohol Review (2023) Vol. 42, Iss. 6, pp. 1482-1492
Open Access | Times Cited: 6
Opioid‐related ambulance attendances during the first 2 years of the COVID‐19 pandemic in Victoria, Australia
Michael McGrath, Mark Stare, Phyllis Chua, et al.
Addiction (2023) Vol. 119, Iss. 2, pp. 348-355
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top